Inhibition of colorectal carcinogenesis by sunitinib malate: disruption of the IL-6/STAT3/c-MYC/TWIST/MMP2 autocrine signaling axis

Inhibition of colorectal carcinogenesis by sunitinib malate: disruption of the IL-6/STAT3/c-MYC/TWIST/MMP2 autocrine signaling axis

Abstract Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor with specificity for VEGFR, KIT, FLT3, and PDGFR, has demonstrated clinical efficacy as a first- to third-line treatment for refractory renal carcinoma. Our previous research indicated that sunitinib malate suppresses intestinal...

Full description

Saved in:
Bibliographic Details
Main Authors: Ling Qian, Yi Yang, Bin Zhao, Pan Xu, Ziyan Hu, Liangwang Zhong, Qi Dai, Youbao Zhong, Chao Yang, Qinglong Shu, Ray P. S. Han, Yang Guan, Zhiming Li, Lai Chen
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Discover Oncology
Subjects:
Sunitinib malate
Colorectal cancer cells
Autocrine IL-6/STAT3 pathway
c-MYC
TWIST
MMP2
Online Access:https://doi.org/10.1007/s12672-025-02498-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s12672-025-02498-z

Similar Items